DexCom, Inc.

$19.00

SKU: DXCM-1 Category:

Description

DexCom, Inc. managed to surpass Wall Street’s revenue and earnings expectations, with organic revenue soaring by 26% in the third quarter of 2023 compared to the same period in 2022. This year is one of the most exciting chapters in the company’s history. G7, building upon DexCom’s legacy of providing the most accurate sensor technology, is gaining traction due to its simplicity and affordability, attracting a growing number of new customers and prescribers. Notably, most G7 customers are newcomers to DexCom, reflecting its success in expanding its prescribing base. Furthermore, DexCom’s G7 software platform continually enhances its value proposition across diverse patient groups through frequent software updates, such as improved connectivity and alarm personalization. This commitment to user-friendly enhancements underscores DexCom’s dedication to improving the customer experience. DexCom’s recent product cycle aligns with its broadest coverage expansion to date, including Medicare coverage for people with type 2 diabetes utilizing basal insulin and certain non-insulin individuals experiencing hypoglycemia. Commercial coverage for this demographic is also rising, reinforcing DexCom’s competitive position.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!